As of 2025-12-17, the EV/EBITDA ratio of Jounce Therapeutics Inc (JNCE) is 1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. JNCE's latest enterprise value is -51.62 mil USD. JNCE's TTM EBITDA according to its financial statements is -48.70 mil USD. Dividing these 2 quantities gives us the above JNCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 15.3x | 14.9x |
| Forward P/E multiples | 21.4x - 26.5x | 21.8x |
| Fair Price | (16.94) - (11.29) | (14.12) |
| Upside | -1001.0% - -700.8% | -850.9% |
| Date | EV/EBITDA |